1xbet 후기 Pharmaceutical Co., Ltd.

1xbet 후기 Pharmaceutical Co., Ltd. (1xbet 후기) announces that AJOVY^®Subcutaneous Injection 225 mg Syringe (generic name is fremanezumab) has received manufacturing and marketing approval in Japan for the indication 1xbet 후기 preventive treatment 1xbet 후기 migraine in adult patients.

AJOVY is a subcutaneous injection 1xbet 후기 the anti-CGRP (calcitonin gene-related peptide) monoclonal antibody, which is produced by recombinant DNA technology. CGRP is thought to play an important role in migraine attacks. Ajovy targets the CGRP ligand, inhibiting its binding to the CGRP receptor.

AJOVY can be administered in two dosing options, either 225 mg once every four weeks or 675 mg once every 12 weeks. The latter dosing option is a unique feature 1xbet 후기 this drug in its drug class.

Migraine is a neurological disorder with a high prevalence, estimated to affect over 10 percent 1xbet 후기 adults worldwide.^*11xbet 후기 Japan the annual prevalence was estimated at 8.4 percent, and the prevalence was highest among women 1xbet 후기 their 30s, reach1xbet 후기g approximately 20 percent.^*2

Makoto Inoue, president and representative director 1xbet 후기 Otsuka Pharmaceutical, commented, "Patients with migraine not only suffer the pain 1xbet 후기 headaches, but also endure a range 1xbet 후기 disabling symptoms impacting their daily lives, such as the uncertainty 1xbet 후기 when the next migraine attack will occur, and the difficulty 1xbet 후기 communicating with those around them when they are suffering the symptoms 1xbet 후기 an attack. While using the experience we have accumulated to address the problems faced by patients, we hope to give support to the lives 1xbet 후기 many patients by providing AJOVY as a new treatment option to those in need."

AJOVY is an asset 1xbet 후기 Teva Pharmaceutical Industries Ltd.

1. 1U.S. National Institute 1xbet 후기 Neurological Disorders and Stroke, 2013
2. 2Sakai F, Igarashi H. Prevalence 1xbet 후기 migraine in Japan: a nationwide survey. Cephalalgia 1997; 17(1): 15-22.